Korro Bio (NASDAQ:KRRO) Announces Quarterly Earnings Results

Korro Bio (NASDAQ:KRRO) issued its quarterly earnings data on Tuesday. The company reported ($2.26) EPS for the quarter, topping analysts’ consensus estimates of ($2.55) by $0.29, Zacks reports.

Korro Bio Trading Down 15.6 %

KRRO stock opened at $55.01 on Thursday. Korro Bio has a twelve month low of $30.00 and a twelve month high of $98.00. The business’s fifty day simple moving average is $49.77 and its two-hundred day simple moving average is $46.92.

Insider Transactions at Korro Bio

In related news, CFO Vineet Agarwal sold 800 shares of Korro Bio stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $70.00, for a total transaction of $56,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on KRRO shares. HC Wainwright reaffirmed a “buy” rating and issued a $115.00 price target on shares of Korro Bio in a report on Wednesday. Raymond James began coverage on Korro Bio in a report on Monday, October 21st. They issued a “strong-buy” rating and a $153.00 target price for the company. Royal Bank of Canada lifted their price objective on shares of Korro Bio from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Monday, October 21st. Finally, William Blair reissued an “outperform” rating on shares of Korro Bio in a research note on Wednesday. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $142.17.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).